L3VLUP
ProSign in

ADPT · AMGN in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ADPTAMGN
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ADPT
  • AMGN
0102030202120222023202420252026
Holders and value by quarter
QuarterADPTAMGN
Q3 202011 holders, $2.2bn16 holders, $16.3bn
Q4 202010 holders, $2.7bn19 holders, $14.0bn
Q1 20216 holders, $1.9bn16 holders, $14.5bn
Q2 20217 holders, $2.0bn23 holders, $13.8bn
Q3 20217 holders, $1.7bn24 holders, $11.6bn
Q4 20217 holders, $1.5bn21 holders, $10.4bn
Q1 20225 holders, $525m23 holders, $9.9bn
Q2 20223 holders, $311m28 holders, $9.7bn
Q3 20223 holders, $281m21 holders, $7.9bn
Q4 20223 holders, $300m24 holders, $9.3bn
Q1 20233 holders, $347m22 holders, $8.4bn
Q2 20233 holders, $272m26 holders, $7.4bn
Q3 20234 holders, $262m26 holders, $8.7bn
Q4 20235 holders, $232m24 holders, $8.4bn
Q1 20243 holders, $131m25 holders, $6.7bn
Q2 20243 holders, $151m20 holders, $8.0bn
Q3 20243 holders, $214m21 holders, $8.8bn
Q4 20244 holders, $239m20 holders, $8.2bn
Q1 20253 holders, $283m25 holders, $12.0bn
Q2 20255 holders, $404m20 holders, $10.2bn
Q3 20255 holders, $503m17 holders, $10.4bn
Q4 20256 holders, $535m19 holders, $18.0bn
Q1 20266 holders, $457m15 holders, $21.4bn
Q2 20267 holders, $946m23 holders, $24.9bn
ADPT

Adaptive Biotechnologies Corp

Holders
3
Reported value
$151m
Buyers
1
Sellers
0

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
AMGN

Amgen Inc

Holders
20
Reported value
$8.0bn
Buyers
11
Sellers
9

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2024

Among the 22 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ADPT (2)

PDT Partners LLC, Viking Global Investors LP

Only AMGN (19)

AllianceBernstein LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Farallon Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →